January 10, 2024 – Laval University in Canada published an article in the scientific journal “Acta Neuropathologica Communications” announcing the possibility of reducing ALS symptoms by reducing inflammation.
Using a genetically engineered mouse model, the team focused on the immune response correlate of reduced synaptic connections between motor neurons in the brain and spinal cord before muscle contraction and loss of motor function begin, and used a semi-synthetic drug derived from the Ashwagandha plant to reduce inflammation and return motor neurons to normal. returned to a normal state.
He also presented the drug as a promising treatment for ALS as well as for inflammation-related diseases such as Alzheimer’s disease.
This could be a promising way to improve ALS symptoms because it reduces inflammation, both sporadic and hereditary.
15 January 2024 Reporter: Yukari Hakansson